S ince the introduction of in vitro fertilization (IVF) in 1978, the number and proportion of children born after assisted conception have increased annually, and currently there are more than 5 million such persons worldwide. 1 Well-recognized perinatal complications in this population include low birth weight, prematurity, and congenital malformations. [2] [3] [4] However, there remains a dearth of population-based studies investigating important but rare health outcomes.
The possibility of an increased risk of cancer in this population has been suggested previously. [5] [6] [7] [8] [9] This concern is supported by the discovery of altered epigenetic patterns in human embryos, 10, 11 cord blood, 12 and placentas 12,13 after assisted conception. Epigenetic defects were also found to be responsible for rare imprinting disorders in unexpectedly large numbers of children born after assisted conception. [14] [15] [16] [17] [18] [19] Epigenetic mechanisms have been shown to play an important role in human carcinogenesis, both as part of and independently of imprinting disorders. 20, 21 A large population-based study investigated this potential risk in a cohort of 26,692 children born after assisted conception in Sweden between 1982 and 2005. 7 A total of 47 cancers (excluding histiocytosis) were observed in this cohort, which had a higher risk of childhood cancer than did children conceived without assisted conception during the same period (odds ratio after the exclusion of infants with histiocytosis, 1.34; 95% confidence interval [CI], 1.02 to 1.76). Although this study was population-based and used registry data collected on a mandatory basis, exploration of individual cancers was limited. Other, albeit smaller, studies have shown similar nonsignificant increases in the overall risk of childhood cancer. [22] [23] [24] We conducted a large population-based linkage study, aiming to provide robust risk estimates for childhood cancer overall and for specific diagnostic subgroups in children born after assisted conception.
Me thods

STUDY POPULATION AND OVERSIGHT
Records relating to children born between January 1, 1992, and December 31, 2008 , in Britain (England, Wales, and Scotland) after non-donorassisted reproduction were identified by the United Kingdom Human Fertilisation and Embryology Authority (HFEA). Non-donor-assisted reproduction was defined as "all treatments or procedures that include the in vitro handling of both human oocytes and sperm, or embryos, for the purpose of establishing a pregnancy," excluding treatments that use donor oocytes, sperm, or embryos. 25 U.K. law mandates the reporting of all assisted conception cycles to the HFEA, including details of the outcome. Thus, the data set can be considered complete. 26 Records relating to 12,930 children conceived after donor cycles in the same time period were not considered, because HFEA statutes prevent the viewing of identifiable data relating to these children by any third party. See Figure S1 in the Supplementary Appendix, available with the full text of this article at NEJM.org, for an overview of inclusions and exclusions.
Approval of the study and a waiver of the requirement for individual written informed consent were obtained from the National Information Governance Board for Health and Social Care and the London Research Ethics Committee. Families can withdraw consent for their HFEA data to be used for research, and 0.3% of families had done so by the time of our study. Their data were not included. All authors assume responsibility for the accuracy and completeness of the data linkage and analysis. The HFEA and the National Registry of Childhood Tumours (NRCT) vouch for the accuracy and completeness of their respective registry data.
OUTCOME DATA
The incidence of cancer was the primary outcome. Clinical details were obtained from the NRCT. A large national population-based childhood cancer registry, the NRCT ascertains validated information from multiple sources regarding children in the United Kingdom who receive a diagnosis of cancer before 15 years of age and is considered almost complete. 27 More than 90% of NRCT records include birth-registration details, which are required for successful data linkage. Records lacking birthregistration information are likely to be for children born outside Britain or adopted children and are therefore extremely unlikely to relate to cohort members. Cancers were classified according to the International Classification of Childhood Cancer, third edition (ICCC-3). 28 Coexisting conditions known at the time of the child's cancer diagnosis are reported to the NRCT by the registering pediatric oncology center. Such information is considered reasonably complete for major congenital anomalies.
DATA LINKAGE
To maximize the sensitivity and specificity of the data linkage, a protocol was developed on the basis of metadata of identified cohort variables (see Table S1 in the Supplementary Appendix). Initially, deterministic linkage was applied to all 106,381 HFEA records of eligible children born after assisted conception and to all 14,896 records of eligible children documented by the NRCT as having been born between 1992 and 2008, with birth-registration details available, and as having received a diagnosis of cancer before January 1, 2009. Deterministic linkage, with the use of SQL software, involved 19 separate linkages of multiple combinations of the following variables: birth weight, date of birth, maternal date of birth, and paternal date of birth. Probabilistic linkage, with the use of Jaro-Winkler software, was applied to the resulting 4,677,887 potential matches with the use of the father's forename and surname, the mother's forename, and any maternal surnames recorded. Two of the authors applied accuracy criteria independently, with confirmation by a third author, and then manually and independently validated 3949 of the most likely matches. Potential matches were excluded when additional information was in conflict, including sex, twin status, date of embryo transfer, treatment center, the mother's forename and surname at birth, the mother's and father's dates of birth, and the mother's and father's places of birth. When the status of the potential match could not be agreed on or when any doubt existed regarding the validity of the match, the third reviewer made the final decision. Additional details of the record-linkage methods are provided in Table S2 in the Supplementary Appendix.
STATISTICAL ANALYSIS
Person-years at risk were calculated from the date of birth until the date of a cancer diagnosis, December 31, 2008, or the child's 15th birthday, whichever came first, and were categorized according to sex, age at diagnosis (0, 1 to 4, 5 to 9, or 10 to 14 years), birth weight, gestational age at birth, singleton or multiple birth, parity, maternal and paternal age, type of assisted conception, fresh or cryopreserved embryos, and cause of parental infertility. To determine the expected number of cancers in the cohort if the risk for cohort members was the same as that for the general population, we used the calculated personyears at risk in conjunction with the NRCT cancer incidence rates for the general population of Britain of the same age during the same period. 29 See Figure S2 in the Supplementary Appendix for details of planned analyses. The number of observed cancers was assumed to follow a Poisson distribution. Standardized incidence ratios, the ratio of observed to expected numbers of cancers, and exact 95% confidence intervals were calculated. P values of less than 0.05, calculated on the basis of the chi-square test, 29 were considered to indicate statistical significance. Analyses were performed with the use of STATA software, version 11. 30 R esult s
Characteristics of the Study Participants
A total of 106,381 children from 83,697 pregnancies, who were conceived by non-donor-assisted conception and born in Britain between 1992 and 2008, were identified from HFEA records. Records for all were included in the data linkage. The year of birth was not available for 368 children, who were therefore excluded from the cohort; the remaining 106,013 children were included in the analysis. Table S3 and Figure S3 in the Supplementary Appendix show the cohort size according to the year of birth and the proportion that each birth year contributed to the total person-years of follow-up. The average duration of follow-up was 6.6 years. A total of 108 children were linked to NRCT records and identified as having received a diagnosis of cancer. Baseline demographic characteristics were similar for cohort members in whom cancer developed and those in whom it did not develop ( Table 1 ). The mean (±SD) age at diagnosis was 4.2±3.3 years. No child in the cohort had more than one recorded diagnosis of cancer.
Overall Cancer Risk
On the basis of a total number of expected cancers of 109.7, the standardized incidence ratio in the study cohort was 0.98 (95% CI, 0.81 to 1. * Plus-minus values are means ±SD. ICSI denotes intracytoplasmic sperm injection, and IVF in vitro fertilization. † When the number of children in whom cancer developed was less than 5, the number is reported as "<5" owing to protection of patient confidentiality, under the terms of the Section 251 approval (National Health Service Act 2006). In these instances, the number of children in whom cancer did not develop has been approximated accordingly. 
Risk According to Cancer Type
For leukemia, neuroblastoma, retinoblastoma, and central nervous system, renal, and germ-cell tumors, no excess risk was found in the study cohort ( Table 2) . One or more coexisting conditions were recorded for 21 children born after assisted conception in whom cancer subsequently developed. Three cases of leukemia were diagnosed, all in children with Down's syndrome, as compared with 1.5 cases of leukemia that would be expected on the basis of NRCT data. No child had any other coexisting condition known to be associated with the development of cancer. All cases of retinoblastoma were unilateral. The number of hepatic tumors (ICCC-3 diagnostic group VII 28 ) in the study cohort was significantly in excess of the expected number (6 vs. 1.8; standardized incidence ratio, 3.27; 95% CI, 1.20 to 7.12; P = 0.03). All were hepatoblastomas, and for this subgroup, the standardized incidence ratio was 3.64 (95% CI, 1.34 to 7.93; P = 0.02; absolute excess risk, 6.21 cases per 1 million person-years). This increase in risk was associated with low birth weight ( Table 3 ). The standardized incidence ratio among children with a birth weight of less than 2500 g was 10.29 (95% CI, 3.34 to 24.02; P = 0.002). Infants with a birth weight of less than 1000 g were at highest risk, with a standardized incidence ratio of 56.96 (95% CI, 6.90 to 205.77; P = 0.01). Coexisting conditions, as recorded by the NRCT, occurred in 3 children and were related to prematurity; none were suggestive of an imprinting disorder. 
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A bone tumor or extraosseous sarcoma (ICCC-3 diagnostic groups VIII and IX 28 ) developed in significantly more children than expected (20 observed vs. 8.6 expected cases; standardized incidence ratio, 2.34; 95% CI, 1.43 to 3.61; P = 0.002). This excess was largely, but not exclusively, accounted for by an excess of rhabdomyosarcomas (10 observed vs. 3.8 expected cases; standardized incidence ratio, 2.62; 95% CI, 1.26 to 4.82: P = 0.02; absolute excess risk, 8.82 cases per 1 million person-years). The risk of rhabdomyosarcoma did not differ significantly according to age at diagnosis, birth weight, or gestational age at birth (Table 3) . Nevertheless, the risk was particularly evident among multiple births, which is surprising because rhabdomyosarcoma is not known to be associated with low birth weight. 31, 32 Results were similar for rhabdomyosarcoma subtypes (data not shown). No coexisting condition consistent with an imprinting disorder was recorded for any of the affected children. The number of cases of rhabdomyosarcoma among children born to fathers older than 40 years of age was significantly greater than the expected number (6 vs. 1.0; standardized incidence ratio, 5.93; 95% CI, 2.18 to 12.90; P = 0.004).
Discussion
No increase in the overall risk of cancer was identified in this cohort study involving 106,013 children younger than 15 years of age who were born in Britain between 1992 and 2008 after assisted conception. We detected 108 cancers as compared with 109.7 expected cancers (standardized incidence ratio, 0.98; 95% CI, 0.81 to 1.19). The narrow confidence interval suggests that a large increased cancer risk in this population is very unlikely. Similarly, no increase in risk was found for most of the childhood cancer subtypes. Significantly increased risks were found only for hepatoblastoma and rhabdomyosarcoma. However, the absolute excess risks for these rare cancers were low, and the absolute excess observed risks between assisted conception and the development of these two tumors are not evidence of causation. They may be explained by chance, underlying parental infertility, or potential mediating factors such as low birth weight, imprinting disorders, or unknown factors. These findings should therefore be interpreted with caution. Our reported standardized incidence ratio and narrow confidence interval for overall cancer risk are consistent with a small increase in the overall risk of cancer shown in a recent systematic review (standardized incidence ratio, 1.32; 95% CI, 1.09 to 1.55) 33 and with a similar finding in a large single study (odds ratio, 1.34; 95% CI, 1.02 to 1.76). 7 There is considerable overlap between the confidence intervals that we present for overall cancer risk and those reported in the latter study. An association between hepatoblastoma and parental infertility has been described previously in a casecontrol study involving 58 affected children (relative risk, 9.2; 95% CI, 2.1 to 31.5). 34 Only 1 of the children was confirmed to have been born after assisted conception; 3 were born after unspecified fertility treatment, and 2 were triplets presumed to have been conceived after fertility treatment.
Subsequent analysis of these data suggested that low birth weight, a known risk factor for the development of hepatoblastoma, 32, 34, 35 is a potential mediating factor. 8 Children born after assisted conception have consistently been shown to be at higher risk for low birth weight and prematurity than children born after spontaneous conception. 2, 3 Similarly, in our study, low birth weight appeared to mediate the association between assisted conception and hepatoblastoma; children with a birth weight of less than 1000 g were at greatest risk. In most cases, low birth weight was related to preterm birth; only 2 of the 6 children with hepatoblastoma had a birth weight below the 10th percentile for gestational age at birth.
A higher risk of imprinting disorders such as the Beckwith-Wiedemann syndrome, caused by epi genetic aberrations (specifically, loss of methylation at the differentially methylated region within KCNQ1 [KvDMR1 locus]), has been reported among children born after assisted conception, as compared with children born after spontaneous conception. [14] [15] [16] [17] [18] [19] Weksberg et al. 36 reported an association between this specific cause of the Beckwith-Wiedemann syndrome and the development of both hepatoblastoma and rhabdomyosarcoma but not Wilms' tumor (which is more commonly associated with uniparental disomy or hypermethylation of a different region of the same gene). Imprinting disorders were also suggested as a potential mediating factor in a previously described association between assisted conception and hepatoblastoma. 8 In our study, none of the 16 children in whom rhabdomyosarcoma or hepatoblastoma developed had an imprinting disorder or a coexisting condition consistent with such a disorder, according to the NRCT data. If imprinting disorders are mediating the association between these two rare tumors and assisted conception, they either are undiagnosed subclinical presentations or have not been reported by physicians.
The main strengths of this study are a large sample, high-quality data from two populationbased data sets, and meticulous linkage of these data sets. Reporting to the HFEA is mandatory, 26 and the NRCT data are virtually complete. 27 Therefore, any child born in Britain between 1992 and 2008 after assisted conception in whom cancer developed before December 31, 2008, is highly likely to have been identified.
Limitations of the study include a lack of censoring for the competing risks of death and emigration, which are likely to be small. Extrapolation from national data for survival to 15 years of age 37 suggests that, under normal circumstances, around 600 members of the original cohort (0.6%) would have died during the study period. Estimation of the numbers lost to follow-up as a result of emigration is more difficult, but it would be reasonable to assume that not more than 2% emigrated. There is no evidence to suggest that these competing risks occur at a greater frequency among children born after assisted conception than among spontaneously conceived children. NRCT cancer registrations were used to calculate the expected incidence of cancer. This rate therefore includes children born after assisted conception, who accounted for 0.5% of all births in Britain in 1992 but for 1.8% in 2008. Because no data were available for deaths and emigrations in the assisted-conception cohort, it was not possible to calculate rates for spontaneously conceived children alone, as a comparison group. We are confident, however, that using overall population rates for comparative purposes has not materially altered our findings.
Although we were able to investigate many potential mediating factors by means of stratification, we were not able to adjust for such factors. Maternal age, parity, smoking status, status with respect to previous miscarriages, and bodymass index have previously been shown not to affect cancer risk in this population. 7 Children from multiple births, including those born after assisted conception, are at significantly lower risk than are singletons. 31, 38, 39 The previously identified potential mediating factors of low birth weight and premature delivery 7 were explored in our study. However, it was not possible to adjust for respiratory diagnoses, shown previously to have a possible effect on cancer risk among children conceived after assisted conception, 7 or to investigate this potential association systematically. However, only 3 of the 108 children in our cohort in whom cancer developed had a coexisting respiratory condition according to the NRCT data.
Our study had an average follow-up of 6.6 years. Because most cases of many types of childhood cancer, including leukemia and all types of embryonal tumors, occur before 6.6 years of age, this study provides good evidence that the risk of these types of tumors among children born after assisted conception is no different than that in the general population. However, for a few diagnostic categories (particularly Hodgkin's lymphoma and bone tumors), the peak incidence occurs in later childhood and adolescence. Therefore, this study provides weaker evidence of the risk of these types of tumors among children born after assisted conception.
In conclusion, our population-based cohort study showed no increase in the overall risk of cancer among children younger than 15 years of age who were born after assisted conception, as compared with the expected risk. This is reassuring for couples considering assisted conception, children conceived in this way, and their families and clinicians. The weaker evidence that we present for increased risks of rare specific cancers needs further exploration to validate these findings and investigate potential causality. These increased risks could be chance findings, but possible alternative explanations include underlying parental infertility and mediation by either low birth weight or imprinting disorders.
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